ES2160643T3 - Composiciones que contienen g-csf y proteina de union al tnf. - Google Patents

Composiciones que contienen g-csf y proteina de union al tnf.

Info

Publication number
ES2160643T3
ES2160643T3 ES95100661T ES95100661T ES2160643T3 ES 2160643 T3 ES2160643 T3 ES 2160643T3 ES 95100661 T ES95100661 T ES 95100661T ES 95100661 T ES95100661 T ES 95100661T ES 2160643 T3 ES2160643 T3 ES 2160643T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
same
csf
acceptable salt
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95100661T
Other languages
English (en)
Inventor
Gottfried Alber
Peter Angehrn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2160643T3 publication Critical patent/ES2160643T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/81Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PRODUCTOS QUE CONTIENEN G-CSF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y UNA PROTEINA AGLUTINANTE TNF, O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, SI SE DESEA UN PORTADOR FARMACEUTICAMENTE ADEPTABLE COMO UNA PREPARACION COMBINADA, EL USO DE UN G-CSF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO , EN LA FABRICACION DE UN MEDICAMENTO PARA LA PROFILAXIS Y/O TRATAMIENTO DE SHOCK SEPTICO DE PACIENTES QUE RECIBEN UNA PROTEINA AGLUTINANTE TNF O UNA SAL FARMACEUTICAMEMTE ACEPTABLE DE LA MISMA, EL USO DE UNA PROTEINA AGLUTINANTE TNF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN LA FABRICACION DE UN MEDICAMENTO PARA LA PROFILAXIS Y TRATAMIENTO DE SHOCK SEPTICO DE PACIENTES QUE RECIBEN UN G-CSF Y UN METODO DE TRATAMIENTO Y/O SHOCK SEPTICO, CUYO METODO COMPRENDE LA ADMINISTRACION TANTO DE PROTEINA TNF O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y UN G-CSF O UNA SAL FARMACEUTICAMENTE ACTIVA DEL MISMO.
ES95100661T 1994-02-04 1995-01-19 Composiciones que contienen g-csf y proteina de union al tnf. Expired - Lifetime ES2160643T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (1)

Publication Number Publication Date
ES2160643T3 true ES2160643T3 (es) 2001-11-16

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95100661T Expired - Lifetime ES2160643T3 (es) 1994-02-04 1995-01-19 Composiciones que contienen g-csf y proteina de union al tnf.

Country Status (16)

Country Link
US (2) US5776895A (es)
EP (1) EP0668077B1 (es)
JP (1) JP2765807B2 (es)
CN (1) CN1097468C (es)
AT (1) ATE202709T1 (es)
AU (1) AU693833B2 (es)
BR (1) BR9500436A (es)
CA (1) CA2139385C (es)
DE (1) DE69521536T2 (es)
DK (1) DK0668077T3 (es)
ES (1) ES2160643T3 (es)
GR (1) GR3036774T3 (es)
NZ (1) NZ270422A (es)
PT (1) PT668077E (es)
RU (1) RU2139084C1 (es)
ZA (1) ZA95679B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
EP1028626A4 (en) * 1997-11-07 2001-05-16 Uab Research Foundation METHOD FOR INCREASING GENE EXPRESSION
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
EP2311485A1 (en) * 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 promotes wound repair
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
ES2370235T3 (es) * 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1572936A2 (en) * 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
RU2207373C1 (ru) * 2002-04-25 2003-06-27 ООО "Новэнерго" Способ получения человеческого гранулоцитарного колониестимулирующего фактора
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CN100563712C (zh) * 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 肿瘤坏死因子结合蛋白的液体制剂
EA200901301A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Полипептиды, вариабельные домены антител и антагонисты
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
EP2318029B1 (en) * 2008-07-23 2017-11-01 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
EP3694535B1 (en) * 2017-10-11 2025-11-26 Elanco US Inc. Porcine g-csf variants and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396158A1 (en) * 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5021551A (en) * 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
AU1235692A (en) * 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法
NZ252542A (en) * 1992-05-05 1997-08-22 Cytel Corp Compositions of blocking p-selectin antibodies and their use in treating inflammatory or thrombotic disease

Also Published As

Publication number Publication date
ZA95679B (en) 1995-08-08
EP0668077A1 (en) 1995-08-23
DE69521536D1 (de) 2001-08-09
BR9500436A (pt) 1995-10-17
CA2139385C (en) 2001-12-25
JP2765807B2 (ja) 1998-06-18
CN1097468C (zh) 2003-01-01
NZ270422A (en) 1996-06-25
PT668077E (pt) 2001-12-28
RU2139084C1 (ru) 1999-10-10
AU1146295A (en) 1995-08-17
US5776895A (en) 1998-07-07
JPH07258300A (ja) 1995-10-09
RU95101385A (ru) 1996-12-27
ATE202709T1 (de) 2001-07-15
EP0668077B1 (en) 2001-07-04
CN1111158A (zh) 1995-11-08
US5750503A (en) 1998-05-12
DK0668077T3 (da) 2001-10-08
DE69521536T2 (de) 2002-04-18
GR3036774T3 (en) 2002-01-31
AU693833B2 (en) 1998-07-09
CA2139385A1 (en) 1995-08-05

Similar Documents

Publication Publication Date Title
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
BG101118A (en) Therapeutical compounds
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
ATE308331T1 (de) Kombinationspräparat enthaltend monozyten- abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
AU623805B2 (en) New use of anti-progestomimetic compounds
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
ATE405276T1 (de) Pharmazeutische gel-zusammensetzung
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
PT907737E (pt) Muteina da il-6
ES2042724T3 (es) Una composicion terapeutica o profilactica.
DE60114844D1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen
FR2645747B1 (fr) Nouvelles compositions pharmaceutiques, leur procede d'obtention et leur emploi en therapeutique tumorale

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 668077

Country of ref document: ES